Welcome to our dedicated page for Mind Medicine news (Ticker: MNMD), a resource for investors and traders seeking the latest updates and insights on Mind Medicine stock.
Mind Medicine Inc. (MNMD) is a clinical-stage biotech company pioneering research into psychedelic-inspired therapies for mental health disorders. This dedicated news hub provides investors and researchers with timely updates on MNMD's scientific advancements, regulatory milestones, and strategic initiatives.
Access official press releases detailing clinical trial progress, partnership announcements with leading research institutions, and analyses of the company's novel approaches to treating conditions like addiction and depression. Our curated collection ensures you stay informed about MNMD's work developing therapies that target neuroplasticity through compounds such as LSD-analogs and psilocybin derivatives.
Key updates include Phase 2 trial results, intellectual property developments, executive leadership changes, and presentations at major medical conferences. All content is sourced from verified channels to maintain compliance with financial disclosure standards.
Bookmark this page for streamlined access to MNMD's evolving story in psychedelic medicine. Check regularly for critical updates about FDA-regulated research programs and breakthrough therapy designation tracking within this emerging biopharmaceutical sector.
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) has announced participation in two upcoming investor conferences. The first event is the
MindMed focuses on developing innovative treatments for brain health disorders targeting neurotransmitter pathways. The company aims to lead in this sector with its pipeline of novel product candidates.
Mind Medicine (MNMD) has achieved a significant milestone in its clinical research by demonstrating the successful results of a double-blind trial on lysergide for treating Major Depressive Disorder (MDD). Conducted by researchers at University Hospital Basel, the study reported statistically significant improvements in MDD symptoms using a high-dose regimen of lysergide. Patients receiving 100 µg and 200 µg doses showed a mean score change of -12.9 compared to -3.6 in the lower dose group, with results maintained for up to 16 weeks post-treatment. The positive outcomes reinforce the drug’s potential in treating MDD and its relevance to MindMed’s MM-120 program focused on Generalized Anxiety Disorder (GAD). The findings were presented on April 14, 2023, in Basel, Switzerland, indicating promising future research and market implications for MindMed.
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) has appointed Mark R. Sullivan as Chief Legal Officer and Corporate Secretary, effective immediately. Sullivan brings extensive legal expertise in the life sciences sector, having previously served as General Counsel for Sesen Bio and MModal Inc. CEO Robert Barrow expressed optimism about Sullivan's contributions during a transformative phase for MindMed, which is advancing its clinical programs targeting brain health disorders. The company is focused on developing innovative treatments and improving patient outcomes. MindMed trades under the symbol MNMD on NASDAQ and MMED on the NEO Exchange.
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) announced its financial results for the full year ended December 31, 2022, reporting cash and equivalents of $142.1 million. The company is focused on key Phase 2 clinical trials, including MM-120 for generalized anxiety disorder (GAD) and ADHD, with topline results expected in late 2023. Additionally, MindMed plans to initiate its first clinical trial of MM-402, targeting autism spectrum disorder (ASD), in 2023. The net loss for 2022 was $56.8 million, a decrease from $93 million in 2021. Management believes the current cash position will fund operations into the first half of 2025.
